An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans
(2007) In Carcinogenesis 28(3). p.625-631- Abstract
- The frequency of micronuclei (MN) in peripheral blood lymphocytes (PBL) is extensively used as a biomarker of chromosomal damage and genome stability in human populations. Much theoretical evidence has been accumulated supporting the causal role of MN induction in cancer development, although prospective cohort studies are needed to validate MN as a cancer risk biomarker. A total of 6718 subjects from of 10 countries, screened in 20 laboratories for MN frequency between 1980 and 2002 in ad hoc studies or routine cytogenetic surveillance, were selected from the database of the HUman MicroNucleus (HUMN) international collaborative project and followed up for cancer incidence or mortality. To standardize for the inter-laboratory variability... (More)
- The frequency of micronuclei (MN) in peripheral blood lymphocytes (PBL) is extensively used as a biomarker of chromosomal damage and genome stability in human populations. Much theoretical evidence has been accumulated supporting the causal role of MN induction in cancer development, although prospective cohort studies are needed to validate MN as a cancer risk biomarker. A total of 6718 subjects from of 10 countries, screened in 20 laboratories for MN frequency between 1980 and 2002 in ad hoc studies or routine cytogenetic surveillance, were selected from the database of the HUman MicroNucleus (HUMN) international collaborative project and followed up for cancer incidence or mortality. To standardize for the inter-laboratory variability subjects were classified according to the percentiles of MN distribution within each laboratory as low, medium or high frequency. A significant increase of all cancers incidence was found for subjects in the groups with medium (RR = 1.84; 95% CI: 1.28-2.66) and high MN frequency (RR = 1.53; 1.04-2.25). The same groups also showed a decreased cancer-free survival, i.e. P = 0.001 and P = 0.025, respectively. This association was present in all national cohorts and for all major cancer sites, especially urogenital (RR = 2.80; 1.17-6.73) and gastro-intestinal cancers (RR = 1.74; 1.01-4.71). The results from the present study provide preliminary evidence that MN frequency in PBL is a predictive biomarker of cancer risk within a population of healthy subjects. The current wide-spread use of the MN assay provides a valuable opportunity to apply this assay in the planning and validation of cancer surveillance and prevention programs. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/668565
- author
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Carcinogenesis
- volume
- 28
- issue
- 3
- pages
- 625 - 631
- publisher
- Oxford University Press
- external identifiers
-
- wos:000245351100012
- scopus:34047154552
- pmid:16973674
- ISSN
- 0143-3334
- DOI
- 10.1093/carcin/bgl177
- language
- English
- LU publication?
- yes
- id
- ff038fca-c9a6-4685-8d34-d035d2ab06dd (old id 668565)
- date added to LUP
- 2016-04-01 12:31:39
- date last changed
- 2022-04-21 08:38:15
@article{ff038fca-c9a6-4685-8d34-d035d2ab06dd,
abstract = {{The frequency of micronuclei (MN) in peripheral blood lymphocytes (PBL) is extensively used as a biomarker of chromosomal damage and genome stability in human populations. Much theoretical evidence has been accumulated supporting the causal role of MN induction in cancer development, although prospective cohort studies are needed to validate MN as a cancer risk biomarker. A total of 6718 subjects from of 10 countries, screened in 20 laboratories for MN frequency between 1980 and 2002 in ad hoc studies or routine cytogenetic surveillance, were selected from the database of the HUman MicroNucleus (HUMN) international collaborative project and followed up for cancer incidence or mortality. To standardize for the inter-laboratory variability subjects were classified according to the percentiles of MN distribution within each laboratory as low, medium or high frequency. A significant increase of all cancers incidence was found for subjects in the groups with medium (RR = 1.84; 95% CI: 1.28-2.66) and high MN frequency (RR = 1.53; 1.04-2.25). The same groups also showed a decreased cancer-free survival, i.e. P = 0.001 and P = 0.025, respectively. This association was present in all national cohorts and for all major cancer sites, especially urogenital (RR = 2.80; 1.17-6.73) and gastro-intestinal cancers (RR = 1.74; 1.01-4.71). The results from the present study provide preliminary evidence that MN frequency in PBL is a predictive biomarker of cancer risk within a population of healthy subjects. The current wide-spread use of the MN assay provides a valuable opportunity to apply this assay in the planning and validation of cancer surveillance and prevention programs.}},
author = {{Bonassi, Stefano and Znaor, Ariana and Ceppi, Marcello and Lando, Cecilia and Chang, Wushou Peter and Holland, Nina and Kirsch-Volders, Micheline and Zeiger, Errol and Ban, Sadayuki and Barale, Roberto and Bigatti, Maria Paola and Bolognesi, Claudia and Cebulska-Wasilewska, Antonina and Fabianova, Eleonora and Fucic, Alexandra and Hagmar, Lars and Joksic, Gordana and Martelli, Antonietta and Migliore, Lucia and Mirkova, Ekaterina and Scarfi, Maria Rosaria and Zijno, Andrea and Norppa, Hannu and Fenech, Michael}},
issn = {{0143-3334}},
language = {{eng}},
number = {{3}},
pages = {{625--631}},
publisher = {{Oxford University Press}},
series = {{Carcinogenesis}},
title = {{An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans}},
url = {{http://dx.doi.org/10.1093/carcin/bgl177}},
doi = {{10.1093/carcin/bgl177}},
volume = {{28}},
year = {{2007}},
}